On Sunday, December 3, CVS announced it had reached an agreement with Aetna for approximately US$69 billion.
The deal is one the year’s largest so far. It comes as insurers are under pressure to lower medical costs and retailers are under attack from new competitors, including an increasingly powerful Amazon. It creates the first health-care triple threat, combining CVS’s pharmacy and pharmacy benefit manager platform with Aetna’s insurance business.
According to the agreed terms, Aetna stockholders will receive US$207 per share, US$145 in cash and US$62 in stock, according to the source. An earlier report by Reuters, which first reported the terms, said Aetna’s board had already approved the deal.
Full Content: Washington Post
Want more news? Subscribe to CPI’s free daily newsletter for more headlines and updates on antitrust developments around the world.
Featured News
Canadian Breadmakers Settle Price-Fixing Lawsuit
Jul 25, 2024 by
CPI
EssilorLuxottica Open to Meta as Shareholder, Says CEO Francesco Milleri
Jul 25, 2024 by
CPI
California Supreme Court Upholds Proposition 22, Securing Independent Contractor Status for Uber and Lyft Drivers
Jul 25, 2024 by
CPI
Paramount Global Investor Sues to Block Skydance Media Merger
Jul 25, 2024 by
CPI
Software Vendors Win Class Action Status in Antitrust Case Against CDK Global
Jul 25, 2024 by
CPI
Antitrust Mix by CPI
Antitrust Chronicle® – International Trade & Antitrust
Jul 26, 2024 by
CPI
What is Wrong with the WTO Discipline on Subsidies?
Jul 26, 2024 by
CPI
The Abiding Tension Between Trade Remedy Law and Antitrust
Jul 26, 2024 by
CPI
Trade and Antitrust: An End to Isolationism
Jul 26, 2024 by
CPI
International Trade Law and Domestic Regulation of Generative Artificial Intelligence: Divergent Approaches?
Jul 26, 2024 by
CPI